Positive News SentimentPositive NewsNASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free OLMA Stock Alerts $11.32 +0.12 (+1.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.80▼$11.5050-Day Range$10.95▼$16.6252-Week Range$3.00▼$17.79Volume499,206 shsAverage Volume1.12 million shsMarket Capitalization$633.01 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Olema Pharmaceuticals alerts: Email Address Olema Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.5% Upside$21.00 Price TargetShort InterestBearish9.05% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$616,000 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.24) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector596th out of 938 stocksPharmaceutical Preparations Industry266th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Olema Pharmaceuticals has a forecasted upside of 85.5% from its current price of $11.32.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.05% of the outstanding shares of Olema Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 3.90%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OLMA. Previous Next 2.6 News and Social Media Coverage News SentimentOlema Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Olema Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $616,000.00 in company stock.Percentage Held by Insiders23.50% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.24) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Olema Pharmaceuticals Stock (NASDAQ:OLMA)Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Read More OLMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OLMA Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by AnalystsMarch 16, 2024 | finance.yahoo.comOLMA Jul 2024 12.500 callMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 16, 2024 | finance.yahoo.comOLMA Apr 2024 22.500 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 25.000 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 10.000 putMarch 13, 2024 | msn.com3 Best Stocks to Buy Now, 3/13/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comBuy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market OpportunityMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 12, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer TreatmentMarch 12, 2024 | markets.businessinsider.comStrong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ PalazestrantMarch 11, 2024 | globenewswire.comOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 6, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer TreatmentMarch 6, 2024 | finance.yahoo.comOlema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsMarch 6, 2024 | globenewswire.comOlema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsMarch 4, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)February 29, 2024 | msn.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?February 17, 2024 | finance.yahoo.comOLMA Mar 2024 20.000 callFebruary 17, 2024 | finance.yahoo.comOLMA Mar 2024 10.000 putJanuary 8, 2024 | finance.yahoo.comOlema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development CandidateJanuary 3, 2024 | seekingalpha.comOlema Pharmaceuticals: Oral SERD Developer With Interesting DataJanuary 2, 2024 | finance.yahoo.comOlema Oncology to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2023 | benzinga.comOlema Pharmaceuticals Stock (NASDAQ:OLMA) Dividends: History, Yield and DatesDecember 21, 2023 | insidermonkey.comHedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and MoreDecember 8, 2023 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals: Strong Safety Profile and Market PositioningDecember 6, 2023 | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals Amid Positive Combination Therapy Study OutcomesSee More Headlines Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/09/2023Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OLMA CUSIPN/A CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$28.00 Low Stock Price Target$18.00 Potential Upside/Downside+85.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.67% Return on Assets-40.99% Debt Debt-to-Equity RatioN/A Current Ratio12.33 Quick Ratio12.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book2.46Miscellaneous Outstanding Shares55,920,000Free Float42,775,000Market Cap$633.01 million OptionableOptionable Beta2.13 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Comp: $726.17kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Comp: $775.48kMr. Geoffrey MogilnerVice President of Investor Relations & CommunicationsMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Comp: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)J.D., Corporate Secretary Comp: $434.32kMs. Sasha Austin CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsPhathom PharmaceuticalsNASDAQ:PHATCogent BiosciencesNASDAQ:COGTNuvation BioNYSE:NUVBSIGA TechnologiesNASDAQ:SIGACalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 995,588 shares on 3/11/2024Ownership: 4.911%Cyrus HarmonSold 25,000 sharesTotal: $310,250.00 ($12.41/share)Perceptive Advisors LLCBought 539,831 shares on 2/26/2024Ownership: 0.980%GSA Capital Partners LLPSold 15,533 shares on 2/16/2024Ownership: 0.080%Price T Rowe Associates Inc. MDSold 14,081 shares on 2/16/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions OLMA Stock Analysis - Frequently Asked Questions Should I buy or sell Olema Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares. View OLMA analyst ratings or view top-rated stocks. What is Olema Pharmaceuticals' stock price target for 2024? 7 analysts have issued 12-month price objectives for Olema Pharmaceuticals' stock. Their OLMA share price targets range from $18.00 to $28.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 85.5% from the stock's current price. View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts. How have OLMA shares performed in 2024? Olema Pharmaceuticals' stock was trading at $14.03 at the beginning of the year. Since then, OLMA stock has decreased by 19.3% and is now trading at $11.32. View the best growth stocks for 2024 here. When is Olema Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OLMA earnings forecast. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Thursday, March, 9th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65). When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), Dimensional Fund Advisors LP (3.11%), First Light Asset Management LLC (1.15%), Victory Capital Management Inc. (1.13%) and Perceptive Advisors LLC (0.98%). Insiders that own company stock include Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G Walmsley Graham, Kinney Horn, Naseem Zojwalla and Sean Bohen. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OLMA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.